**Patient Name:** Pierre Cassin  
**MRN:** 004281556  
**DOB:** 1995-06-10 (Age: 28)  
**Sex:** M  
**Date of Admit:** 2024-05-11  
**Date of Note:** 2024-05-23  
**Attending:** Dr. Angela L. Hsu  
**Location:** ICUâ€“Cardiac  

---

### **History of Present Illness**

28-year-old male with PMH significant for obesity (BMI ~31), viral sinusitis, viral pharyngitis, and remote concussion (no LOC), presented with 3 days of progressive dyspnea, orthopnea, and chest tightness. He initially attributed symptoms to a viral URI but developed worsening fatigue and lower extremity edema. On day of admission, found diaphoretic and hypotensive (SBP 82) at home. EMS noted tachycardia and O2 sat 91% on RA. On arrival, patient was in frank cardiogenic shock with rising lactate (4.8) and was admitted to the cardiac ICU. Initial TTE showed LVEF 10-15% with global hypokinesis. Given persistent shock despite maximal medical therapy, he underwent emergent placement of a percutaneous left ventricular assist device (Impella CP) on hospital day 2.

---

### **Hospital Course Overview**

- **Day 1-2:** Cardiogenic shock, hypotension, AKI (creatinine peaked at 2.1), lactic acidosis. Poor response to pressors/inotropes. Transferred to cath lab for Impella placement.
- **Day 2-4:** Gradual improvement in end-organ perfusion. Pressors weaned. Serial TTEs showed improvement in LVEF to 25%. Developed mild transaminitis and thrombocytopenia.
- **Day 5-8:** Impella weaned and removed on day 7. Diuresed aggressively. Extubated on day 6. Persistent mild AKI, improving.
- **Day 9-11:** Stable on floor. Ongoing diuresis. Mobilization with PT. Discharge planning initiated.

---

## **Assessment/Problem List**

### 1. **Cardiogenic Shock due to Acute Severe Systolic Heart Failure**

- **Summary:** Likely viral myocarditis (post-viral syndrome). Required Impella CP for hemodynamic support.
- **Status:** LVEF improved to 35% pre-discharge. Off pressors, euvolemic.
- **Plan:**
  - Continue GDMT for HFrEF (low-dose carvedilol, lisinopril, spironolactone).
  - Follow up with heart failure and transplant team.
  - Serial echo.
  - Monitor for arrhythmias.

### 2. **Obesity (BMI 31)**

- **Plan:** Nutrition consult. Caloric restriction, low sodium diet, cardiac rehab referral.

### 3. **Acute Kidney Injury (AKI), resolving**

- **Etiology:** Likely multifactorial (shock, nephrotoxic meds, diuretics).
- **Plan:** Monitor renal function. Avoid nephrotoxins. Adjust meds for GFR.

### 4. **Transaminitis**

- **Etiology:** Likely ischemic hepatitis (shock liver).
- **Plan:** Monitor LFTs. No hepatotoxic meds.

### 5. **Thrombocytopenia**

- **Etiology:** Multifactorial (device-related, sepsis, dilutional).
- **Plan:** Monitor CBC daily. No evidence of HIT.

### 6. **Remote concussion, viral sinusitis, viral pharyngitis**

- **Plan:** Continue supportive care. No acute issues.

### 7. **Allergies**

- **NKDA.** EpiPen on hand for possible anaphylaxis (history of urticaria with unknown trigger).

---

## **Medications**

| Medication                     | Dose/Route                     | Frequency             | Indication                      |
|---------------------------------|-------------------------------|-----------------------|----------------------------------|
| Carvedilol                     | 3.125 mg PO                   | BID                   | Systolic HF                     |
| Lisinopril                     | 2.5 mg PO                     | Daily                 | Systolic HF                     |
| Spironolactone                 | 12.5 mg PO                    | Daily                 | Systolic HF                     |
| Furosemide                     | 20 mg IV/PO                   | BID                   | Volume overload                  |
| Loratadine                     | 5 mg chewable                  | PRN                   | Allergic rhinitis                |
| Epinephrine (auto-injector)    | 0.3 ml (1mg/ml)                | PRN                   | Allergy kit                      |
| Acetaminophen                  | 650 mg PO                     | q6h PRN               | Fever/pain                       |
| Pantoprazole                   | 40 mg IV                      | Daily                 | GI prophylaxis                   |

---

## **Vital Signs (Selected)**

| Date        | Temp (C) | HR  | BP         | RR | SpO2 | Wt (kg) |
|-------------|----------|-----|------------|----|------|---------|
| 5/11        | 37.7     | 132 | 82/58      | 24 | 91%  | 95.4    |
| 5/12        | 38.1     | 128 | 88/62      | 22 | 94%  | 96.0    |
| 5/13        | 37.2     | 110 | 102/70     | 18 | 97%  | 94.5    |
| 5/15        | 36.9     | 92  | 110/75     | 16 | 98%  | 92.2    |
| 5/17        | 37.0     | 84  | 115/80     | 15 | 98%  | 91.0    |
| 5/21        | 36.8     | 78  | 120/80     | 14 | 98%  | 90.5    |

---

## **Laboratory Results**

### **CBC, CHEM7, LFTs, Cardiac Markers**

| Date    | WBC  | Hgb  | Hct  | Plt  | Na   | K   | Cl   | CO2  | BUN  | Cr   | Glu  | AST  | ALT  | T.Bili | Troponin | BNP     |
|---------|------|------|------|------|------|-----|------|------|------|------|------|------|------|--------|----------|---------|
| 5/11    | 6.1  | 16.1 | 49.6 | 198  | 132  | 5.2 | 104  | 19   | 32   | 1.8  | 124  | 89   | 105  | 2.1    | 0.32     | 7,050   |
| 5/12    | 8.2  | 14.3 | 43.1 | 155  | 129  | 4.8 | 100  | 16   | 39   | 2.1  | 118  | 212  | 187  | 3.0    | 0.41     | 6,300   |
| 5/13    | 7.8  | 13.9 | 41.2 | 132  | 135  | 4.2 | 103  | 23   | 26   | 1.5  | 110  | 101  | 85   | 1.7    | 0.15     | 4,800   |
| 5/15    | 6.9  | 14.8 | 44.9 | 141  | 138  | 4.0 | 106  | 25   | 21   | 1.2  | 105  | 49   | 51   | 0.9    | 0.09     | 2,300   |
| 5/16    |      | 15.1 |      | 158  | 139  |     | 107  |      | 19   | 1.1  | 103  | 41   | 40   |        |          | 1,580   |
| 5/18    | 5.6  | 15.6 | 46.2 | 172  | 140  | 4.1 |      | 27   | 17   | 1.0  | 108  | 38   |      | 0.7    | 0.04     | 980     |
| 5/21    | 5.2  | 15.3 |      | 196  | 141  | 4.1 | 108  | 28   | 16   | 0.9  | 99   |      | 27   |        | 0.01     | 540     |

*Note: Some labs not obtained on all days. Significant for initial leukocytosis, anemia, thrombocytopenia, hyperbilirubinemia, marked transaminitis, and elevated BNP/troponin trending down.*

---

## **Imaging**

- **TTE (5/11):** LVEF 10-15%, global hypokinesis, mild RV dysfunction, no LV thrombus, mild MR.
- **TTE (5/15):** LVEF 25%, improved wall motion, no pericardial effusion.
- **CXR (5/11):** Mild pulmonary edema, vascular congestion.
- **CXR (5/13):** Improving pulmonary edema, Impella in place.

---

## **Procedures**

- **5/12:** Impella CP placement via right femoral artery (see full procedure note).
- **5/13-5/15:** Serial TTE for device position.
- **5/17:** Right heart cath: Normal wedge, improved cardiac index.

---

## **Consults**

- **Cardiology (Heart Failure):** Guideline-directed therapy, transplant eval.
- **Nutrition:** Calorie/salt restriction.
- **PT/OT:** Mobilization post-ICU.
- **Nephrology:** AKI management.

---

## **Discharge Planning**

- Anticipate discharge home with family support.
- Close follow-up with cardio, HF clinic, PCP.
- Home weight monitoring, BP log, HF education.
- Prescriptions for GDMT, diuretics, EpiPen.

---

## **Problem-Based Assessment and Plan**

1. **Acute Systolic Heart Failure/Cardiogenic Shock:**  
   - Etiology: Suspect viral myocarditis (consider endomyocardial biopsy if recurrent).  
   - Plan: GDMT, close follow-up, repeat echo, life vest until rhythm stable.

2. **Obesity:**  
   - Plan: Nutrition, exercise, PT/OT, sleep apnea screening.

3. **AKI, resolving:**  
   - Plan: Avoid nephrotoxins, monitor labs, renal dosing.

4. **Shock Liver:**  
   - Plan: Repeat LFTs, supportive care.

5. **Thrombocytopenia:**  
   - Plan: Monitor, trend, avoid unnecessary sticks.

6. **Allergy hx:**  
   - Plan: Continue EpiPen, allergy f/u PRN.

7. **Others:**  
   - Plan: Resume loratadine PRN, monitor for infection, vaccinate as indicated.

---

**Attending:** Angela L. Hsu, MD  
**Resident:** Jacob R. Lee, MD  
**Date/Time Signed:** 2024-05-23 13:41

---

**END OF NOTE**
